CAMILLE MARKHAM: Open Payments
NPI 1972114023 · BRADENTON, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,857 in 128 payments from 19 companies in 2025. Trend: 2023 $3,405 · 2024 $3,695 · 2025 $2,857
Food & beverage: $2,857
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $373 |
| Neurocrine BioSciences, Inc. | 11 | $336 |
| Alkermes, Inc. | 13 | $287 |
| ABBVIE INC. | 18 | $258 |
| Teva Pharmaceuticals USA, Inc. | 9 | $232 |
| Vanda Pharmaceuticals Inc. | 10 | $223 |
| E.R. Squibb & Sons, L.L.C. | 9 | $203 |
| Lundbeck LLC | 8 | $201 |
| Tris Pharma Inc | 10 | $168 |
| Corium, LLC | 6 | $138 |
Products named: CAPLYTA, INGREZZA, ARISTADA, REXULTI, VRAYLAR, AUSTEDO XR, COBENFY, FANAPT.
Industry payments across FL — which companies pay providers there.
